Theranovir’s metabolic program focuses on NOV3, an innovative monoclonal antibody targeting the biological root of obesity rather than its symptoms. Current obesity treatments often struggle to maintain long-term results, as many patients regain weight after therapy ends. Theranovir's work targets mechanisms that contribute to leptin resistance, a key factor in persistent obesity and metabolic imbalance. The goal is to restore healthy leptin-dependent NRP-1/OBR function, helping to regulate appetite, reduce inflammation, and support sustainable weight management. Preclinical studies have shown promising results in improving body weight and blood glucose levels.

Obesity is not only a major health challenge affecting over a billion people worldwide, but it also carries significant economic and societal costs. It contributes to increased healthcare spending, reduced workforce productivity and higher rates of associated chronic diseases such as diabetes and cardiovascular conditions. Effective, long lasting therapies could therefore have a transformative impact, reducing healthcare burdens, improving quality of life and supporting healthier societies globally.